Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index
ABSTRACTBackground. Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are emerging as an essential part of the standard of care for proteinuria in patie
academic.oup.com
September 3, 2026 at 6:02 PM
Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Risk of #ketoacidosis varies greatly by patient characteristics. As risk is not confined to shortly after treatment initiation, it should be considered throughout treatment, & patients should be instructed to pause therapy during acute illness & stress www.thelancet.com/journals/lan...
#DKA #SGLT2is
#DKA #SGLT2is
September 3, 2026 at 6:44 AM
Risk of #ketoacidosis varies greatly by patient characteristics. As risk is not confined to shortly after treatment initiation, it should be considered throughout treatment, & patients should be instructed to pause therapy during acute illness & stress www.thelancet.com/journals/lan...
#DKA #SGLT2is
#DKA #SGLT2is
10/10
Final thoughts💡
Always look past the primary endpoint headline! KDIGO is useful, but you must understand drug physiology to read it.
MERCURI-2 nearly halved KDIGO AKI, but whether SGLT2is prevent AKI beyond oliguria remains unsettled.
The peri-op 👑is still up for grabs.
Final thoughts💡
Always look past the primary endpoint headline! KDIGO is useful, but you must understand drug physiology to read it.
MERCURI-2 nearly halved KDIGO AKI, but whether SGLT2is prevent AKI beyond oliguria remains unsettled.
The peri-op 👑is still up for grabs.
August 19, 2026 at 1:09 AM
10/10
Final thoughts💡
Always look past the primary endpoint headline! KDIGO is useful, but you must understand drug physiology to read it.
MERCURI-2 nearly halved KDIGO AKI, but whether SGLT2is prevent AKI beyond oliguria remains unsettled.
The peri-op 👑is still up for grabs.
Final thoughts💡
Always look past the primary endpoint headline! KDIGO is useful, but you must understand drug physiology to read it.
MERCURI-2 nearly halved KDIGO AKI, but whether SGLT2is prevent AKI beyond oliguria remains unsettled.
The peri-op 👑is still up for grabs.
SGLT2i in gout reduces gout med use. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) diabetesjournals.org/care/article...
Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies
OBJECTIVE. Sodium–glucose cotransporter 2 inhibitors (SGLT2is) lower serum urate and are associated with a lower risk of recurrent gout flares. We used tar
diabetesjournals.org
July 20, 2026 at 11:00 PM
SGLT2i in gout reduces gout med use. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) diabetesjournals.org/care/article...
#ansky today’s #periop learning - SGLTi’s - you can be a bit less cautious about stopping them periop now: @bjaeducation.bsky.social
www.bjanaesthesia.org/article/S000...
www.bjanaesthesia.org/article/S000...
Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
The perioperative management of patients using sodium-glucose cotransporter 2 inhibitors
(SGLT2is) remains controversial. The US Food and Drug Administration currently recommends
stopping SGLT2is for ...
www.bjanaesthesia.org
July 15, 2026 at 4:04 AM
#ansky today’s #periop learning - SGLTi’s - you can be a bit less cautious about stopping them periop now: @bjaeducation.bsky.social
www.bjanaesthesia.org/article/S000...
www.bjanaesthesia.org/article/S000...
Now it’s a drug used to treat type 2 diabetes that seems to lower dementia risk is certain older patients. bit.ly/4eWPRRC
Lower Dementia Risk Seen With SGLT2is in Seniors 65+ With Mood, Psychotic Disorders
THURSDAY, July 9, 2026 (HealthDay News) -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is associated with a lower risk for dementia in older adults wit
bit.ly
July 10, 2026 at 1:57 PM
Now it’s a drug used to treat type 2 diabetes that seems to lower dementia risk is certain older patients. bit.ly/4eWPRRC
【日本人DKDに対するフィネレノン追加経験/DOM】May31
日本、RASi・SGLT2阻害薬服用DKD 252例解析——
・フィネレノン「追加」 [可能] 群では「非追加」に比べ24カ月間
の尿蛋白が相対的に47%の有意減少。
・一方、eGFR低下には群間に有意差なし。
・フィンレノン追加に伴うカリウム上昇は開始後早期のみ。
抄録🔗 x.gd/u6pM7
日本、RASi・SGLT2阻害薬服用DKD 252例解析——
・フィネレノン「追加」 [可能] 群では「非追加」に比べ24カ月間
の尿蛋白が相対的に47%の有意減少。
・一方、eGFR低下には群間に有意差なし。
・フィンレノン追加に伴うカリウム上昇は開始後早期のみ。
抄録🔗 x.gd/u6pM7
Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
Background Despite treatment with renin–angiotensin system inhibitors (RASis) and sodium–glucose cotransporter 2 inhibitors (SGLT2is), diabetic kidney disease (DKD) continues to exhibit substantial ...
x.gd
June 1, 2026 at 10:39 PM
【日本人DKDに対するフィネレノン追加経験/DOM】May31
日本、RASi・SGLT2阻害薬服用DKD 252例解析——
・フィネレノン「追加」 [可能] 群では「非追加」に比べ24カ月間
の尿蛋白が相対的に47%の有意減少。
・一方、eGFR低下には群間に有意差なし。
・フィンレノン追加に伴うカリウム上昇は開始後早期のみ。
抄録🔗 x.gd/u6pM7
日本、RASi・SGLT2阻害薬服用DKD 252例解析——
・フィネレノン「追加」 [可能] 群では「非追加」に比べ24カ月間
の尿蛋白が相対的に47%の有意減少。
・一方、eGFR低下には群間に有意差なし。
・フィンレノン追加に伴うカリウム上昇は開始後早期のみ。
抄録🔗 x.gd/u6pM7
That's comparing the risk of depression between those who use GLP‐1s and those who use SGLT2is. It's not an overall analysis of risk in GLP-1 users, it's that GLP-1 users have more risk than SGLT2is users. Also the cohort is entirely adults with type 2 diabetes.
May 24, 2026 at 1:50 PM
That's comparing the risk of depression between those who use GLP‐1s and those who use SGLT2is. It's not an overall analysis of risk in GLP-1 users, it's that GLP-1 users have more risk than SGLT2is users. Also the cohort is entirely adults with type 2 diabetes.
In This Month in T1D Research (Apr 2026) we talk about
- Gene editing to hide beta cells,
- GLP1s and SGLT2is providing benefit to T1Ds,
- Ketogenic diets in children,
- The limits of AID systems for pregnant T1Ds,
- The link between T1D and dementia and the consequences.
youtu.be/41l5wdvzXbo
- Gene editing to hide beta cells,
- GLP1s and SGLT2is providing benefit to T1Ds,
- Ketogenic diets in children,
- The limits of AID systems for pregnant T1Ds,
- The link between T1D and dementia and the consequences.
youtu.be/41l5wdvzXbo
This Month in Type 1 Diabetes Research Apr 2026
YouTube video by This Month in Type 1 Diabetes Research
youtu.be
May 24, 2026 at 6:50 AM
In This Month in T1D Research (Apr 2026) we talk about
- Gene editing to hide beta cells,
- GLP1s and SGLT2is providing benefit to T1Ds,
- Ketogenic diets in children,
- The limits of AID systems for pregnant T1Ds,
- The link between T1D and dementia and the consequences.
youtu.be/41l5wdvzXbo
- Gene editing to hide beta cells,
- GLP1s and SGLT2is providing benefit to T1Ds,
- Ketogenic diets in children,
- The limits of AID systems for pregnant T1Ds,
- The link between T1D and dementia and the consequences.
youtu.be/41l5wdvzXbo
7/10
More questions ❓ #NephJC
Given the high burden of HTN/DM, was CKD likely underdiagnosed (3%) at baseline & could unrecognized CKD have altered the safety of intensive BP lowering?
Were there differences between groups in the use of kidney-protective agents such as RAASi, or SGLT2is?
More questions ❓ #NephJC
Given the high burden of HTN/DM, was CKD likely underdiagnosed (3%) at baseline & could unrecognized CKD have altered the safety of intensive BP lowering?
Were there differences between groups in the use of kidney-protective agents such as RAASi, or SGLT2is?
May 20, 2026 at 1:49 AM
7/10
More questions ❓ #NephJC
Given the high burden of HTN/DM, was CKD likely underdiagnosed (3%) at baseline & could unrecognized CKD have altered the safety of intensive BP lowering?
Were there differences between groups in the use of kidney-protective agents such as RAASi, or SGLT2is?
More questions ❓ #NephJC
Given the high burden of HTN/DM, was CKD likely underdiagnosed (3%) at baseline & could unrecognized CKD have altered the safety of intensive BP lowering?
Were there differences between groups in the use of kidney-protective agents such as RAASi, or SGLT2is?
En los pacientes con gota y diabetes tipo 2, los SGLT2i puede reducir el uso de medicamentos relacionados con la gota, y la exposición a los efectos dañinos de los AINES sobre riñón, metabolismo y CV #SGLT2i #gout #t2d diabetesjournals.org/care/article...
Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies
OBJECTIVE. Sodium–glucose cotransporter 2 inhibitors (SGLT2is) lower serum urate and are associated with a lower risk of recurrent gout flares. We used tar
diabetesjournals.org
April 20, 2026 at 2:14 PM
En los pacientes con gota y diabetes tipo 2, los SGLT2i puede reducir el uso de medicamentos relacionados con la gota, y la exposición a los efectos dañinos de los AINES sobre riñón, metabolismo y CV #SGLT2i #gout #t2d diabetesjournals.org/care/article...
Happy to share my first first-author paper here :)
@ucsdpharmacy.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...
#pharmacoepidemiology #ucsd #ucsandiego #hwsph #sspps #acei #sglt2i
@ucsdpharmacy.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...
#pharmacoepidemiology #ucsd #ucsandiego #hwsph #sspps #acei #sglt2i
Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium‐Glucose Cotransporter 2 Inhibitors
Purpose
Both angiotensin-converting enzyme inhibitors (ACEis) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide cardiovascular and renal benefits in Type 2 Diabetes (T2D) patients, sug.....
onlinelibrary.wiley.com
March 21, 2026 at 5:11 AM
Happy to share my first first-author paper here :)
@ucsdpharmacy.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...
#pharmacoepidemiology #ucsd #ucsandiego #hwsph #sspps #acei #sglt2i
@ucsdpharmacy.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...
#pharmacoepidemiology #ucsd #ucsandiego #hwsph #sspps #acei #sglt2i
An estimated 148 million US adults meet FDA-approved indications for at least one #CKM therapy, including 11 million with eligibility for all three medication classes.
ja.ma/4aZvLTs
ja.ma/4aZvLTs
March 17, 2026 at 12:00 PM
An estimated 148 million US adults meet FDA-approved indications for at least one #CKM therapy, including 11 million with eligibility for all three medication classes.
ja.ma/4aZvLTs
ja.ma/4aZvLTs
The use of SGLT2is does not negatively impact the 1-year amputation rate or healing rate of DFU. One-year mortality was lower in patients treated with an SGLT2i.
March 15, 2026 at 9:23 PM
The use of SGLT2is does not negatively impact the 1-year amputation rate or healing rate of DFU. One-year mortality was lower in patients treated with an SGLT2i.
The use of SGLT2i inhibitors does not negatively impact the one-year amputation rate or healing rate of diabetic foot ulcer. One-year mortality was lower in patients treated with SGLT2 inhibitors.
Read here ➡️ doi.org/10.2337/dc25-2001
Read here ➡️ doi.org/10.2337/dc25-2001
March 13, 2026 at 6:30 PM
The use of SGLT2i inhibitors does not negatively impact the one-year amputation rate or healing rate of diabetic foot ulcer. One-year mortality was lower in patients treated with SGLT2 inhibitors.
Read here ➡️ doi.org/10.2337/dc25-2001
Read here ➡️ doi.org/10.2337/dc25-2001
New population-based study (n=229,300 T2D): GLP-1RAs & SGLT2is showed no ↑ or ↓ in overall autoimmune rheumatic disease risk vs. DPP4is. But SGLT2is were linked to ~50% ↓ risk of systemic ARDs. Study led by Dr. @derinkaracabeyli.bsky.social. See infographic 👇
February 17, 2026 at 5:38 PM
New population-based study (n=229,300 T2D): GLP-1RAs & SGLT2is showed no ↑ or ↓ in overall autoimmune rheumatic disease risk vs. DPP4is. But SGLT2is were linked to ~50% ↓ risk of systemic ARDs. Study led by Dr. @derinkaracabeyli.bsky.social. See infographic 👇
Yeah, as Brian told, SGLT2is are benign drugs, however till they're proven to be effective - it would definitely constitute a risk. #NephJC
February 11, 2026 at 2:59 AM
Yeah, as Brian told, SGLT2is are benign drugs, however till they're proven to be effective - it would definitely constitute a risk. #NephJC
Yes, so scientifically we're justified in giving SGLT2is early. The risks of infections, and altered physiology - they're another story though! #NephJC
February 11, 2026 at 2:17 AM
Yes, so scientifically we're justified in giving SGLT2is early. The risks of infections, and altered physiology - they're another story though! #NephJC
I am much more convinced of the benefits of SGLT2is and GLP-1s than say, Entresto, as their effects (especially of SGLT2is) are replicated and triangulated in multiple trials (rather than based on the torture of one trial).
I don't see why they would work in the acute setting though.
I don't see why they would work in the acute setting though.
January 30, 2026 at 5:45 PM
I am much more convinced of the benefits of SGLT2is and GLP-1s than say, Entresto, as their effects (especially of SGLT2is) are replicated and triangulated in multiple trials (rather than based on the torture of one trial).
I don't see why they would work in the acute setting though.
I don't see why they would work in the acute setting though.
Sorry that it was dropped! My interpretation of DEFENDER is the same as yours, it makes me think it is safe to start SGLT2is early in the CICU in heart failure, and as diuretic adjuncts.
January 28, 2026 at 8:26 PM
Sorry that it was dropped! My interpretation of DEFENDER is the same as yours, it makes me think it is safe to start SGLT2is early in the CICU in heart failure, and as diuretic adjuncts.